PAI
ELEV

Palo Alto Investors’s Elevation Oncology ELEV Stock Holding History

Palo Alto Investors’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,298,097
Closed -$779K – 45
2024
Q3 		$779K Sell
1,298,097
-502,009
-28% -$744K 0.1% 38
2024
Q2 		$4.86M Buy
1,800,106
+453,440
+34% +$1.71M 0.56% 24
2024
Q1 		$6.91M Buy
+1,346,666
New +$4.36M 0.78% 26

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Palo Alto Investors's ELEV Position: Q4 2024 in Review

Palo Alto Investors sold out of Elevation Oncology (ELEV) in Q4 2024, closing a stake of 1,298,097 shares — an estimated $779K sold.

Palo Alto Investors first reported a position in ELEV in Q1 2024 and held it in 3 quarters. The position peaked at $6.91M in Q1 2024. 71 funds tracked by Wall St. Rank hold ELEV as of Q4 2024.

  • Palo Alto Investors reported no remaining Elevation Oncology position as of Q4 2024 after selling out during the quarter.
  • Palo Alto Investors sold 1,298,097 Elevation Oncology shares in Q4 2024, an estimated $779K.
  • Palo Alto Investors first reported a position in Elevation Oncology in Q1 2024 and held it in 3 quarters.
  • Palo Alto Investors's Elevation Oncology position peaked at $6.91M in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2024.

Based on Palo Alto Investors's 13F filing for Q4 2024, filed 14 Feb 2025.